Navigation Links
EUROPLASMA: Résultats consolidés 2012
Date:9/26/2013

at net contributif déficitaire de (16 488) K€ et constitue la zone de perte la plus importante. Cette perte inclut des éléments non cash significatifs dont :

  • une dépréciation de 3 875 K€ comptabilisée sur les titres mis en équivalence de CHO Morcenx au regard du retard de la Take Over Date et du remplacement du gazéifieur qui a engendré une période d'arrêt prolongée : l'usine doit être remise en route fin 2013 début 2014 pour une livraison le 28 février 2014 et une montée en puissance dans les mois qui suivront. Les hypothèses de rendement et de flux de trésorerie pourront donc être réappréciées sur la base des performances réellement constatées en 2014 ;
  • une dépréciation de 3 750 K€ comptabilisée sur les 7 500 K€ versés en garantie au titre du contrat d'EPC afin de tenir compte du risque de mise en jeu par CHO Morcenx de cette garantie.

Tout ou partie des ces dépréciations pourra faire l'objet de reprises sur des exercices ultérieurs en fonction des performances de la centrale électrique à Morcenx et du montant des garanties finalement libérées à la livraison définitive de la centrale.

Flux de trésorerie et bilan

En milliers d'euros (KEUR) 31/12/2012 31/12/2011 Variation Actifs non courants 46 055 48 631 -2 576 -5% Actifs courants 26 941 39 863 -12 922 -32% Capitaux Propres - Part du Groupe 13 808 34 556 -20 748 -60% Intérêts hors groupe 2 133 2 446 -313 -13% Dettes financières non courantes 19 753 11 997 7 756 65% Autres passifs non courants 1 648 1 523 125 8% Dettes financières courantes 3 803 3 500 303 9% Autres passifs courants 31 853 34 472 -2 619 -8% Endettement net - 19 501 -3 535 -15 9
'/>"/>

SOURCE Europlasma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  Now available is a stem cell ... Regenerative Therapies , located in Guadalajara, Mexico ... people a new health option: stem cell therapies ... countless patients suffer from joint and muscle injuries due ... tears, torn rotator cuff, tennis elbow, and knee injuries. ...
(Date:7/24/2014)... by group leader Yung-Eun Sung has announced that ... and nitrogen-doped graphenes which can be applied as ... cells. Yung-Eun Sung is both a group leader ... for Basic Science* (IBS) and a professor at ... great significance with regards to the development of ...
(Date:7/24/2014)... , July 24, 2014 Research and ... "Global Cell Culture Market 2014-2018" report to their ... Cell culture is the in vitro growth of ... research, cell studies, and biopharmaceutical production. Cell culture is ... Cell culture instruments and cell culture consumables are necessary ...
(Date:7/24/2014)... N.J. , July 24, 2014  CorMedix ... on developing and commercializing therapeutic products for the ... today announces receipt of notice on July 18, ... the NYSE-MKT has accepted the CorMedix plan to ... NYSE-MKT. As a result, the NYSE-MKT is continuing ...
Breaking Biology Technology:Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Global Cell Culture Market 2014-2018: Key Vendors are Becton, Dickinson and Co, EMD, GE Healthcare, Lonza Group, Sigma Aldrich and Thermo Fisher Scientific 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3
... BIRMINGHAM, Ala., Oct. 31 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... quarter ended September 30, 2008., Third Quarter ... ended September 30, 2008, the Company reported,collaborative and ... to $20.5 million for the three months ended ...
... and waves erode billions of tons of soil from ... plagued with excessive amounts of suspended sediment. According to ... the largest nonpoint source pollution in the environment. , ... obvious wind, water and wave forces breaking apart particles ...
... 30 AVAX Technologies, Inc.,(OTC Bulletin Board: AVXT) ... it closed a bridge loan financing pursuant to ... by the Amendment to Convertible,Note and Warrant Purchase ... Company sold convertible promissory notes,(the "Notes") in the ...
Cached Biology Technology:BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 9Virginia Tech engineers identify conditions that initiate erosion 2Virginia Tech engineers identify conditions that initiate erosion 3AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing 2
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... of native animal species for food or commercial food ... factor in the decline of many species of primates ... that more than half of the species being consumed ... "By surveying not only the meat made available for ... the forest by hunters and brought to villages for ...
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Creating sustainable STEM teacher preparation programs 2
... drug for cocaine addiction and overdose, Journal of the ... what they term the most powerful substance ever discovered for ... to the world,s first effective medicine for fighting overdoses and ... the Sept. 24 issue of the Journal of the ...
... A researcher at Oregon State University has used ... to identify counties in Oregon with high numbers of ... in fighting the illegal drug. The study, presented ... from four sources then identified five counties with the ...
... a muscle fiber mesh at the neuromuscular junction. New work ... Cell Biology reveals that an extracellular matrix protein called ... fit together type="rel"doi="10.1083/jcb.2008. , A neuromuscular junction, or synapse, in ... nerve terminal meeting a flat, oval structure on the muscle ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Sept. 10, 2008 2American Chemical Society's Weekly PressPac -- Sept. 10, 2008 3American Chemical Society's Weekly PressPac -- Sept. 10, 2008 4American Chemical Society's Weekly PressPac -- Sept. 10, 2008 5American Chemical Society's Weekly PressPac -- Sept. 10, 2008 6American Chemical Society's Weekly PressPac -- Sept. 10, 2008 7American Chemical Society's Weekly PressPac -- Sept. 10, 2008 8New method identifies meth hot spots 2New method identifies meth hot spots 3
Ms anti-Cyclophilin D...
Protein Kinase D2 Immunogen: Human protein kinase D2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Request Info...
Immunogen: Recombinant rabbit tryptophan hydroxylase, isolated as inclusion bodies from E. coli and purified by preparative SDS-PAGE. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: